The Brugada syndrome

Gerald Naccarelli, Charles Antzelevitch, Deborah Wolbrette, Jerry C. Luck

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

The Brugada syndrome describes a subgroup of patients at risk for the occurrence of ventricular fibrillation who have no definable structural heart disease associated with a right bundle branch block conduction pattern and ST-segment elevation in the right precordial leads. This syndrome is caused by genetic defects in the alpha subunit of the sodium channel. This defect causes a reduction in the sodium channel current, which accentuates the epicardial action potential notch leading to ST-segment elevation. Sodium channel blockers can potentiate these findings and screen for patients with intermittent baseline electrocardiographic findings. Because of the poor prognosis of such patients, symptomatic patients should be treated with an implantable cardioverter-defibrillator.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalCurrent Opinion in Cardiology
Volume17
Issue number1
DOIs
StatePublished - Jan 29 2002

Fingerprint

Brugada Syndrome
Sodium Channels
Sodium Channel Blockers
Bundle-Branch Block
Implantable Defibrillators
Ventricular Fibrillation
Action Potentials
Heart Diseases

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Naccarelli, Gerald ; Antzelevitch, Charles ; Wolbrette, Deborah ; Luck, Jerry C. / The Brugada syndrome. In: Current Opinion in Cardiology. 2002 ; Vol. 17, No. 1. pp. 19-23.
@article{93d36b87284d4dbcb2435e21233b44f7,
title = "The Brugada syndrome",
abstract = "The Brugada syndrome describes a subgroup of patients at risk for the occurrence of ventricular fibrillation who have no definable structural heart disease associated with a right bundle branch block conduction pattern and ST-segment elevation in the right precordial leads. This syndrome is caused by genetic defects in the alpha subunit of the sodium channel. This defect causes a reduction in the sodium channel current, which accentuates the epicardial action potential notch leading to ST-segment elevation. Sodium channel blockers can potentiate these findings and screen for patients with intermittent baseline electrocardiographic findings. Because of the poor prognosis of such patients, symptomatic patients should be treated with an implantable cardioverter-defibrillator.",
author = "Gerald Naccarelli and Charles Antzelevitch and Deborah Wolbrette and Luck, {Jerry C.}",
year = "2002",
month = "1",
day = "29",
doi = "10.1097/00001573-200201000-00003",
language = "English (US)",
volume = "17",
pages = "19--23",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

The Brugada syndrome. / Naccarelli, Gerald; Antzelevitch, Charles; Wolbrette, Deborah; Luck, Jerry C.

In: Current Opinion in Cardiology, Vol. 17, No. 1, 29.01.2002, p. 19-23.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The Brugada syndrome

AU - Naccarelli, Gerald

AU - Antzelevitch, Charles

AU - Wolbrette, Deborah

AU - Luck, Jerry C.

PY - 2002/1/29

Y1 - 2002/1/29

N2 - The Brugada syndrome describes a subgroup of patients at risk for the occurrence of ventricular fibrillation who have no definable structural heart disease associated with a right bundle branch block conduction pattern and ST-segment elevation in the right precordial leads. This syndrome is caused by genetic defects in the alpha subunit of the sodium channel. This defect causes a reduction in the sodium channel current, which accentuates the epicardial action potential notch leading to ST-segment elevation. Sodium channel blockers can potentiate these findings and screen for patients with intermittent baseline electrocardiographic findings. Because of the poor prognosis of such patients, symptomatic patients should be treated with an implantable cardioverter-defibrillator.

AB - The Brugada syndrome describes a subgroup of patients at risk for the occurrence of ventricular fibrillation who have no definable structural heart disease associated with a right bundle branch block conduction pattern and ST-segment elevation in the right precordial leads. This syndrome is caused by genetic defects in the alpha subunit of the sodium channel. This defect causes a reduction in the sodium channel current, which accentuates the epicardial action potential notch leading to ST-segment elevation. Sodium channel blockers can potentiate these findings and screen for patients with intermittent baseline electrocardiographic findings. Because of the poor prognosis of such patients, symptomatic patients should be treated with an implantable cardioverter-defibrillator.

UR - http://www.scopus.com/inward/record.url?scp=0036148980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036148980&partnerID=8YFLogxK

U2 - 10.1097/00001573-200201000-00003

DO - 10.1097/00001573-200201000-00003

M3 - Review article

C2 - 11790929

AN - SCOPUS:0036148980

VL - 17

SP - 19

EP - 23

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 1

ER -